Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using 68Ga-Pentixafor for Tumor Localization in Cushing

Yue Wu1, Yanfei Wu1, Boyuan Yao1

  • 1From the Department of Radiology (Yue Wu, S.W., W.R., Z. Yao), Department of Neurosurgery, Shanghai Pituitary Tumor Center (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.), Department of Nuclear Medicine and PET Center (Yanfei Wu, S.R., Y.G., F.X.), and Department of Endocrinology (M.H., S.Z., Y.Y., H.Y., Z.Z.), Huashan Hospital, Fudan University, 12 Wulumuqi Road, Shanghai 200040, China; Neurosurgical Institute of Fudan University, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China (B.Y., Z. Ye, R.H., N.Q., Y. Zhang, X.Y., Z.M., Y. Wang, Y. Zhao, Q.Z.); and Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Neuroendocrine Unit, Massachusetts General Hospital, and Harvard Medical School, Boston, Mass (Q.Z.).

Radiology
|December 17, 2024
PubMed

Related Concept Videos